- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | Gain Therapeutics reports 81% reduction in Parkinson's biomarker | 1 | Investing.com | ||
| 22.12.25 | Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data | 1 | Investing.com | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 3 | GlobeNewswire (USA) | ||
| 18.12.25 | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.25 | Gain Therapeutics, Inc.: Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease | 416 | GlobeNewswire (Europe) | Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever... ► Artikel lesen | |
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.12.25 | Gain Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 01.12.25 | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data | 12 | Investing.com | ||
| 28.11.25 | Gain Therapeutics reicht Prospektnachtrag für Aktienangebot über 35,5 Mio. USD ein | 2 | Investing.com Deutsch | ||
| 28.11.25 | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.11.25 | Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 | 1 | Seeking Alpha | ||
| 16.10.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Attend the 2025 Maxim Growth Summit | 4 | GlobeNewswire (USA) | ||
| 14.10.25 | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.10.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 2 | GlobeNewswire (USA) | ||
| 06.10.25 | Gain Therapeutics meldet vorläufige Phase-1b-Daten für Parkinson-Medikament GT-02287 | 2 | Investing.com Deutsch | ||
| 06.10.25 | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.10.25 | Gain Therapeutics reports positive early data from Parkinson's trial | 1 | Investing.com | ||
| 06.10.25 | Gain Therapeutics, Inc.: Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders | 3 | GlobeNewswire (USA) | ||
| 23.09.25 | Gain Therapeutics, Inc.: Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 | 2 | GlobeNewswire (USA) | ||
| 18.09.25 | Gain Therapeutics extends Phase 1b Parkinson's treatment study | 3 | Investing.com |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAGE LABS | 15,900 | +3,25 % | BioAge Labs, Inc.: BioAge Announces Pricing of Upsized $115.0 Million Public Offering | EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 2,970 | 0,00 % | Quince Therapeutics: Citizens bestätigt "Market Outperform"-Rating und Kursziel von 8 US-Dollar | ||
| FRACTYL HEALTH | 2,170 | 0,00 % | Fractyl Health und BioAge Labs: Weitere Top-Renditen im NBC! | Mit Fractyl Health und BioAge Labs blicken Mitglieder des No Brainer Club auf die nächsten großen Renditebringer in ihren Depots. Beide Empfehlungen konnten sich in den letzten Monaten im Wert verdoppeln.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,63 | +0,04 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 294,04 | 0,00 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| QIAGEN | 46,430 | 0,00 % | AKTIE IM FOKUS: Qiagen testen Dreijahreshoch - Übernahmefantasie als Treiber | FRANKFURT (dpa-AFX) - Nach einem Sprung auf den höchsten Stand seit Februar 2023 hat die Aktie von Qiagen am Donnerstag ihre Gewinne fast vollständig abgegeben. Zuletzt ging es nur noch um 0,5 Prozent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,860 | +3,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| VERA THERAPEUTICS | 47,220 | -0,57 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,560 | +0,42 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,960 | +1,37 % | ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? | ||
| NUVALENT | 106,01 | 0,00 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,590 | 0,00 % | Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns | ||
| ARCELLX | 68,55 | +1,26 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ERASCA | 9,605 | -3,56 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,000 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE... ► Artikel lesen |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -5,12 % bei einem Aktienkurs von 1,945 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.